California State Teachers Retirement System Raises Stock Holdings in Pfizer Inc. $PFE

California State Teachers Retirement System lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 2,320.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,981,455 shares of the biopharmaceutical company's stock after purchasing an additional 208,976,273 shares during the quarter. California State Teachers Retirement System owned 3.82% of Pfizer worth $5,248,993,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Norges Bank bought a new position in shares of Pfizer in the 4th quarter valued at about $1,830,986,000. Bank of America Corp DE purchased a new stake in Pfizer during the second quarter valued at approximately $1,049,602,000. BlackRock Inc. raised its position in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. Morgan Stanley lifted its stake in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PFE shares. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and cut their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s latest quarterly results exceeded expectations, with adjusted earnings of $0.77 per share versus the $0.68 consensus and revenue of $15.03 billion versus estimates of $14.40 billion. The results helped revive the stock after a prolonged downturn and reinforced management’s full-year 2026 EPS guidance of $2.80-$3.00. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Analysts point to Pfizer’s non-COVID portfolio, oncology pipeline and cost-cutting initiatives as potential growth and margin supports. These factors could help offset falling COVID product sales and extend the company’s recovery. Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
• Neutral Sentiment: Pfizer will present at the Morgan Stanley Global Healthcare Conference on September 14. Chief Executive Albert Bourla’s comments could provide updates on the pipeline, capital allocation and the company’s strategy for managing patent losses. Pfizer Invites Public to Listen to Webcast
• Neutral Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension product. The transaction may generate cash and streamline Pfizer’s portfolio, but its financial impact appears limited relative to Pfizer’s roughly $159 billion market value. Novartis India Acquires Pfizer Brands
• Negative Sentiment: Jim Cramer selected Johnson & Johnson over Pfizer among healthcare stocks, a high-profile preference that may weigh on Pfizer’s relative appeal. Another comparison favored AbbVie as a stronger dividend-growth investment, despite Pfizer’s roughly 6% yield. Jim Cramer Picks J&J Over Pfizer

Pfizer Trading Up 0.1%

Shares of NYSE PFE opened at $27.82 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The business's 50 day moving average price is $26.21 and its 200-day moving average price is $26.35. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.21. The company has a market cap of $158.58 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 1.87 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.